Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials

Annals of Internal Medicine

Volumn 168, Issue 8, 2018, Pages 605-606

  Prorok, Philip C ^a   Miller, Anthony B ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PROSTATE CANCER; EARLY CANCER DIAGNOSIS; MASS SCREENING; PROSTATE TUMOR; RESEARCH;

EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH;

EID: 85045891681     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/L17-0735     Document Type: Letter

References (4)

1. Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449-55. [PMID: 28869989] doi:10 .7326/M16-2586
2. Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123:592-9. [PMID: 27911486] doi:10 .1002/cncr.30474
3. Miller AB. Prostate cancer screening. In: Miller AB, ed. Epidemiologic Studies in Cancer Prevention and Screening. Statistics for Biology and Health. Vol. 79. New York: Springer-Verlag; 2013:277-85.
4. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-34. [PMID: 22801674] doi:10.7326/0003-4819-157-2-201207170-00459